Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting

Western Journal of Emergency Medicine

Volumn 17, Issue 2, 2016, Pages 165-172

  Zeller, Scott L ^a,b   Citrome, Leslie ^c  

^a Alameda Health System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Agitation; Antipsychotic; BETA guidelines; Bipolar disorder; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; LOXAPINE;

AGITATION; AWARENESS; BIPOLAR DISORDER; COOPERATION; DISEASE ASSOCIATION; EMERGENCY HEALTH SERVICE; EMERGENCY PHYSICIAN; EMERGENCY WARD; HUMAN; MEDICAL ASSESSMENT; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA; SKILL; COMPLICATION; DISEASE MANAGEMENT; HOSPITAL EMERGENCY SERVICE; INHALATIONAL DRUG ADMINISTRATION; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PSYCHOMOTOR AGITATION;

ADMINISTRATION, INHALATION; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DISEASE MANAGEMENT; EMERGENCY SERVICE, HOSPITAL; HUMANS; LOXAPINE; PRACTICE GUIDELINES AS TOPIC; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; SOCIETIES, MEDICAL;

EID: 84962613498     PISSN: 1936900X     EISSN: 19369018     Source Type: Journal    
DOI: 10.5811/westjem.2015.12.28763     Document Type: Review

References (43)

1. Holloman GH Jr and Zeller SL. Overview of project BETA: Best practices in Evaluation and Treatment of Agitation. West J Emerg Med. 2012;13(1):1-2.
2. Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med. 2012;13(1):26-34.
3. Knox DK and Holloman GH Jr. Use and avoidance of seclusion and restraint: consensus statement of the American Association for Emergency Psychiatry Project BETA Seclusion and Restraint Workgroup. West J Emerg Med. 2012;13(1):35-40.
4. Weiss AP, Chang G, Rauch SL, et al. Patient- And practice-related determinants of emergency department length of stay for patients with psychiatric illness. Ann Emerg Med. 2012;60(2):162-71.
5. Marder SR. A review of agitation in mental illness: Treatment guidelines and current therapies. J Clin Psychiatry. 2006;67 Suppl 10:13-21.
6. National Institute for Health and Care Excellence (NICE). Bipolar disorder: The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. Available at: Www.nice.org.uk/guidance/cg185. 2014. Accessed Sep 11, 2015.
7. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263-306.
8. Richmond JS, Berlin JS, Fishkind AB, et al. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med. 2012;13(1):17-25.
9. Stowell KR, Florence P, Harman HJ, et al. Psychiatric evaluation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychiatric Evaluation Workgroup. West J Emerg Med. 2012;13(1):11-6.
10. Nordstrom K, Zun LS, Wilson MP, et al. Medical evaluation and triage of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA Medical Evaluation Workgroup. West J Emerg Med. 2012;13(1):3-10.
11. Strout TD. Psychometric testing of the Agitation Severity Scale for acute presentation behavioral management patients in the emergency department. Adv Emerg Nurs J. 2014;36(3):250-70.
12. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the Behavioural Activity Rating Scale (BARS): A novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87-95.
13. Kopecky HJ, Kopecky CR, Yudofsky SC. Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients. Psychiatr Q. 1998;69(4):301-23.
14. Silver JM and Yudofsky SC. The Overt Aggression Scale: overview and guiding principles. J Neuropsychiatry Clin Neurosci. 1991;3(2):S22-9.
15. Montoya A, Valladares A, Lizan L, et al. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.
16. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004;68(2-3):331-7.
17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
18. Zeller SL and Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403-25.
19. Pines JM, Batt RJ, Hilton JA, et al. The financial consequences of lost demand and reducing boarding in hospital emergency departments. Ann Emerg Med. 2011;58(4):331-40.
20. R. Reducing restraint use in a trauma center emergency room. Nurs Clin North Am. 2014;49:371-81.
21. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511-8.
22. Morrow T. Old drug in new package promises to calm the agitated. Manag Care. 2014;23(4):50-1.
23. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11 Suppl 1:5-108; quiz 110-2.
24. Janssen Pharmaceuticals, Inc. Haldol Prescribing Information. Available at: Www.janssenpharmaceuticalsinc.com/assets/Haldol-USPI-0911.pdf. 2013. Accessed Sep 11, 2015.
25. Jhee SS, Zarotsky V, Mohaupt SM, et al. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol. Ann Pharmacother. 2003;37(10):1434-7.
26. Pfizer Inc. Geodon Prescribing Information. 2014. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=584. Accessed Sep 11, 2015.
27. Eli Lilly and Company. Zyprexa Prescribing Information. 2014. Available at: Pi.lilly.com/us/zyprexa-pi.pdf. Accessed Sep 11, 2015.
28. Otsuka Pharmaceutical Company. Abilify Prescribing Information. 2012. Available at: Packageinserts.bms.com/pi/pi-abilify.pdf Accessed Sep 11, 2015.
29. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876-85.
30. Janssen Pharmaceuticals, Inc. Risperdal Prescribing Information. 2014. Available at: Www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf. Accessed Sep 11, 2015.
31. Teva Pharmaceuticals USA I. Adasuve Prescribing Information. 2015. Available at: Www.adasuve.com/PDF/AdasuvePI.pdf Accessed Sep 11, 2015.
32. Nordstrom K and Allen MH. Alternative delivery systems for agents to treat acute agitation: Progress to date. Drugs. 2013;73(16):1783-92.
33. Van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25:1687-99.
34. Thyssen A, Remmerie B, D'Hoore P, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: A summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther. 2007;29(2):290-304.
35. Actavis Inc. Saphris Prescribing Information. 2015. Available at: Pi.actavis.com/data-stream.asp?product-group=1908&p=pi. Accessed Sep 11, 2015.
36. Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61-8.
37. Zisook S and Click MA Jr. Evaluations of loxapine succinate in the ambulatory treatment of acute schizophrenic episodes. Int Pharmacopsychiatry. 1980;15(6):365-78.
38. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51-8.
39. Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: A multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31-40.
40. Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235- 45.
41. Zedie N, Amory DW, Wagner BK, et al. Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Clin Pharmacol Ther. 1996;59(3):341-8.
42. Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2012;11:CD009377.
43. Citrome L. Review: Limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression. Evid Based Ment Health. 2013;16(2):47.